Lifecore Biomedical Inc. (LFCR)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $243.36M
Last updated: Nov 17, 2026 at 11:03 AM ET
Lifecore Biomedical Inc. (LFCR) Stock Forecast
Analysts expect Lifecore Biomedical (LFCR) to earn -$0.55 per share in the fiscal year ending May 31, 2027, on revenue of $147.73M. Of 5 analysts, 0 rate the stock Buy or Strong Buy, 5 Hold and 0 Sell or Strong Sell, for a consensus of Hold. Over the last 30 days, 0 estimates for the fiscal year ending May 31, 2027 were revised up and 1 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 5 ratings average 3.00, inside the Hold band from 2.5 up to 3.5. All 5 rate it Hold.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 0 | 0.0% |
| Buy | 0 | 0.0% |
| Hold | 5 | 100.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Hold
- Total analysts
- 5
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
- Fiscal year ending May 31, 2027
- -$0.55
- EPS consensus, revenue $147.73M
- Fiscal year ending Dec 31, 2027
- -$0.88
- EPS consensus, revenue $131.39M
- Next report
- Feb 5, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| May 31, 2027 | -$0.55 | -$0.66 to -$0.43 | 2 | $147.73M | $146.06M to $150.33M | 4 |
| Dec 31, 2027 | -$0.88 | -$1.08 to -$0.76 | 4 | $131.39M | $130.30M to $134.37M | 4 |
Quarterly Estimates
The EPS consensus falls from -$0.10 for the quarter ending Dec 31, 2026 to -$0.28 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.10 | -$0.14 to -$0.05 | 4 | $37.89M | $37.89M to $37.89M | 1 |
| Mar 31, 2027 | -$0.28 | -$0.30 to -$0.27 | 3 | $27.10M | $25.39M to $29.57M | 3 |
Estimate Revisions
Across the 4 periods below, the last 30 days brought 0 upward and 1 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending May 31, 2027 | 0 | 1 |
| Fiscal year ending Dec 31, 2027 | 0 | 0 |
| Quarter ending Dec 31, 2026 | 0 | 0 |
| Quarter ending Mar 31, 2027 | 0 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending May 31, 2027 has worsened from -$0.43.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending May 31, 2027 | -$0.55 | -$0.45 | -$0.45 | -$0.45 | -$0.43 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.88 | -$0.89 | -$0.88 | -$0.88 | -$0.99 | N/A |
| Quarter ending Dec 31, 2026 | -$0.10 | -$0.09 | -$0.10 | -$0.10 | -$0.18 | N/A |
| Quarter ending Mar 31, 2027 | -$0.28 | -$0.29 | -$0.28 | -$0.28 | -$0.30 | N/A |
Frequently Asked Questions About LFCR
What is the LFCR stock forecast?
Consensus analyst estimates put Lifecore Biomedical's EPS at -$0.55 for the fiscal year ending May 31, 2027, on revenue of $147.73M. The consensus rating from 5 analysts is Hold.
How do analysts rate LFCR stock?
Of 5 analysts covering Lifecore Biomedical, 0 rate it Strong Buy, 0 Buy, 5 Hold, 0 Sell and 0 Strong Sell, for a consensus of Hold.
What EPS do analysts expect from LFCR next year?
For the fiscal year ending May 31, 2027, the consensus EPS estimate is -$0.55, with estimates from -$0.66 to -$0.43 from 2 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.88, with estimates from -$1.08 to -$0.76 from 4 analysts.
What revenue do analysts expect from Lifecore Biomedical next year?
For the fiscal year ending May 31, 2027, the consensus revenue estimate is $147.73M, with estimates from $146.06M to $150.33M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $131.39M, with estimates from $130.30M to $134.37M.
How many analysts cover LFCR?
5 analysts rate Lifecore Biomedical stock, and 2 analysts estimate its EPS for the fiscal year ending May 31, 2027.
LFCR pages: Overview, Earnings, Forecast, Financials, Competitors